ASX pot-stock MGC Pharma mixes up first CannEpil™ batch
MGC Pharmaceuticals (ASX:MXC) this morning revealed that its European medicinal cannabis manufacturing facility is today producing the first batch of CannEpilTM, following the receipt of its interim Good Manufacturing Practice (GMP) certification.
This sizeable milestone kicks off following delivery of pharmaceutical-grade THC compound to the company’s manufacturing facility and approval from the European authorities.
Analysis of the first batch will commence shortly to confirm that GMP production protocols have been followed. Critically, this will be the final step in the process before full certification is granted, after which the facility will be one of the most advanced in Europe for pharmaceutical-grade medical cannabis production.
Once granted, MXC will be able to begin full-scale commercial production of CannEpil, and to produce additional pharmaceutical-grade medical cannabis products for use by the company in clinical studies, research pipelines and additional medical products licensed for distribution.
CannEpil is MGC Pharma’s first pharmaceutical-grade medical cannabis product, targeting drug-resistant forms of epilepsy (also known as refractory epilepsy), which accounts for around 30 per cent of the 240,000 people diagnosed with epilepsy in Australia each year.
Once distribution of CannEpil begins, moreover, it is set to generate significant revenues for MXC, expected to be around $1 million per year from its first full year of distribution. Notably, this is from less than 100 patients already registered through MXC’s relationship with Epilepsy Action Australia (EAA).
CannEpil be distributed in Australia under MGC Pharma’s agreement with specialist Australian pharmaceutical distributor, HL Pharma.
It’s worth noting here that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
MXC co-founder and CEO, Roby Zomer, said: “This is an exciting final step for MGC Pharma as we focus on completing full GMP certification of our manufacturing facility, allowing us to produce CannEpil in Europe and focus on significantly progressing our medical research and development of our pharmaceutical products pipeline.”
“The production of our first CannEpil batch is a milestone, and leaves us well-positioned to achieve certification and commence full-scale commercial production in the next few months.”
This most recent development — a sizeable landmark for the $103.4 million-capped biotech junior — has put MXC on a considerable high. The company’s share price has surged on the back of this morning’s announcement, currently sitting at 8.9 cents.
Past performance is not necessarily indicative of future results. As part of the due diligence process, investors must consider all factors over and above the past performance of the product. Investors should not engage with a product solely on it past performance.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.